We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Protagonist Therapeutics Inc
16 own
13 watching
Current Price
$40.27
$-1.3
(-3.13%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
2,337.13M
52-Week High
42.67000
52-Week Low
13.72000
Average Volume
0.74M
Dividend Yield
--
P/E Ratio
--
Market Capitalization2,337.13M52-Week High42.6700052-Week Low13.72000Average Volume0.74MDividend Yield--P/E Ratio--What does the Protagonist Therapeutics Inc do?
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Read More
How much money does Protagonist Therapeutics Inc make?
News & Events about Protagonist Therapeutics Inc.
Accesswire
1 year ago
Phase 2b FRONTIER 1 data presentation at World Congress of Dermatology highlights that a greater proportion of patients achieved 75, 90 and 100 percent improvement in skin clearance at week 16 in comparison to placeboPhase 3 development in moderate-to-severe plaque psoriasis and Phase 2b...
Accesswire
1 year ago
NEWARK, CA / ACCESSWIRE / June 9, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ('Protagonist' or 'the Company') announced today that Ronald Hoffman, MD, Icahn School of Medicine at Mount Sinai, provided a press briefing this morning on the late-breaking oral presentation...
Accesswire
1 year ago
NEWARK, CA / ACCESSWIRE / April 4, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ('Protagonist' or the 'Company') today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per...
PR Newswire
1 year ago
Thinking about buying stock in Protagonist Therapeutics, BP, Nio, Axsome Therapeutics, or Petroleo Brasileiro? Thinking about buying stock in Protagonist Therapeutics, BP, Nio, Axsome Therapeutics, or Petroleo Brasileiro? PR Newswire NEW YORK, Oct. 3, 2022 NEW YORK, Oct. 3, 2022 /PRNewswire...
Ticker Report
2years ago
Protagonist Therapeutics (NASDAQ:PTGX Get Rating) was downgraded by StockNews.com from a hold rating to a sell rating in a note issued to investors on Friday. Several other equities analysts have also recently issued reports on the company. Piper Sandler decreased...
Frequently Asked Questions
Frequently Asked Questions
What is Protagonist Therapeutics Inc share price today?
Can Indians buy Protagonist Therapeutics Inc shares?
How can I buy Protagonist Therapeutics Inc shares from India?
Can Fractional shares of Protagonist Therapeutics Inc be purchased?
What are the documents required to start investing in Protagonist Therapeutics Inc stocks?
What is today’s traded volume of Protagonist Therapeutics Inc?
What is today’s market capitalisation of Protagonist Therapeutics Inc?
What is the 52-Week High and Low Range of Protagonist Therapeutics Inc?
What percentage is Protagonist Therapeutics Inc down from its 52-Week High?
What percentage is Protagonist Therapeutics Inc up from its 52-Week Low?
Current Price
$40.27
$-1.3
(-3.13%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.